FDAsafety guidance66% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Trodelvy; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Antibody-Drug Conjugate
- Sub-indication
- General
Related signal: FDA Approves Supplemental Application for Trodelvy (Sacituzumab Govitecan-Hziy)